Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
"This acquisition is further evidence of Graceway’s proven practice of working with industry leading companies, like Gilead, to acquire and develop cutting edge compounds and technologies. The transaction with Gilead today is similar to our previous transaction with Pfizer in that we have licensed important compounds, processes, and intellectual properties that we hope will lead to exciting products for the treatment of important dermatological conditions faced by patients," stated Jefferson J. Gregory, Chairman and CEO of Graceway.
A topical version of GS 9191 was evaluated for the treatment of external genital warts in a recently completed Phase 2 study. GS 9191 was well tolerated and statistically significantly superior to placebo in this proof of concept study. These results suggest GS 9191 could be a potential treatment for skin conditions characterized by excessive cellular proliferation.
Obesity crisis in the U.S. expected to worsen by 2050